EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives

Etienne Bizot iD, Vincent Portet Sulla, Christelle Vauloup-Fellous, Marie-Anne Rameix-Welti, Vincent Gajdos, Nabila Seddiki

Pediatric Allergy and Immunology · 2025-12 · 36 (12)

DOI: 10.1111/pai.70257 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 05.12.2025. Verfasst von Etienne Bizot und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases » (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, F…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Antibodies, Monoclonal, Antibodies, Viral. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation pour la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The burden of respiratory syncytial virus (RSV) remains a major global health concern in early childhood, responsible for substantial morbidity, hospitalizations, and deaths, particularly in infants under 6 months. For over two decades, palivizumab was the only monoclonal antibody (mAb) available for prophylaxis, restricted to high‐risk groups due to cost and limited duration of protection. Recent advances in structural virology and antibody engineering have led to the emergence of long‐acting mAbs, notably nirsevimab and clesrovimab, which offer single‐dose seasonal protection and are now shifting RSV prevention strategies from high‐risk targeting to universal infant immunization. These antibodies act by locking the RSV fusion (F) protein in its pre‐fusion conformation, thereby preventing viral entry, with nirsevimab targeting site Ø and clesrovimab targeting site IV. Real‐world implementation has demonstrated remarkable reductions in RSV hospitalizations, aligning with clinical trial results, while large‐scale safety data support their favorable tolerance. However, the paradigm shift brings new challenges: understanding breakthrough infections, assessing long‐term immune imprinting, and anticipating viral evolution under immunological pressure. The risk of antigenic escape and the consequences of passive immunization on long‐term B‐cell memory development—especially in breakthrough cases—remain critical and underexplored immunological frontiers. This review explores the molecular and immunological underpinnings of RSV‐targeted mAbs, evaluates current real‐world evidence, and outlines future directions—including bispecific antibodies and nanobody‐based therapies—that could further transform RSV prophylaxis. Sustained genomic surveillance and a deeper understanding of host immunity will be crucial to preserve the long‐term efficacy of these innovations in pediatric infectious disease prevention. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanAntibodies, MonoclonalAntibodies, ViralAntiviral AgentsHumansInfantAnimalsViral Fusion ProteinsInfant, NewbornPalivizumab

Stichwörter der Autor:innen

RSVbronchiolitismonoclonal antibodypediatricpreventionvaccine

Substanzen

Antibodies, MonoclonalAntibodies, ViralAntiviral AgentsViral Fusion ProteinsPalivizumab

Autor:innen und Institutionen

  • Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases » (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Fontenay-Aux-Roses, Le Kremlin-Bicêtre, France.
  • General Pediatrics and Pediatric Emergencies, Antoine-Béclère Hospital, Paris Saclay University Hospital, AP-HP, Clamart, France.
  • Division of Virology, WHO Rubella National Reference Laboratory, National Reference Laboratory for Perinatal Viral Infections, Department of Biology Genetics, Paris Saclay University Hospital, AP-HP, Paris, France.
  • Virology Department, Hôpital Ambroise Paré, Paris Saclay University Hospital, AP-HP, Paris, France.
  • Centre for Research in Epidemiology and Population Health, INSERM, Villejuif, France.
  • IHU-SEPSIS Comprehensive Center, Garches, France.

ORCID-Profile: Etienne Bizot

Förderung

  • Fondation pour la Recherche Médicale

Zitieren

APA

Bizot, E., Portet Sulla, V., Vauloup-Fellous, C., Rameix-Welti, M. A., Gajdos, V., & Seddiki, N. (2025). Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives. Pediatric Allergy and Immunology, 36(12). https://doi.org/10.1111/pai.70257

Vancouver

Bizot E, Portet Sulla V, Vauloup-Fellous C, Rameix-Welti MA, Gajdos V, Seddiki N. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives. Pediatric Allergy and Immunology. 2025;36(12). doi:10.1111/pai.70257

BibTeX
@article{Bizot2025,
  author = {Bizot, Etienne and Portet Sulla, Vincent and Vauloup-Fellous, Christelle and Rameix-Welti, Marie-Anne and Gajdos, Vincent and Seddiki, Nabila},
  title = {Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives},
  journal = {Pediatric Allergy and Immunology},
  year = {2025},
  volume = {36},
  number = {12},
  doi = {10.1111/pai.70257}
}
Kostenlos starten →